The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
En Beyond Health Lab ofrecemos BPC-157 10mg en forma de polvo liofilizado con pureza verificada por HPLC, para investigadores que buscan un material de referencia estable y reproducible
Nerve Healing Potential : Laboratory studies explore possible neuroprotective effects, which may relate to recovery from nerve-related damage
Since at least seven of the panels 14 members have ties to the peptide industry or clinics promoting them, its expected theyll advise removing the restrictionseven though FDA scientists in June recommended against doing so, citing insufficient evidence on the peptides effectiveness and safety